In contrast to the current immunotherapy approaches described above, natural killer T (NKT) cells (4–6), but not other effector cell types, have the potential to simultaneously activate various effector cell types, including both CD8 T and NK cells that, in turn, eliminate both MHC-positive and MHC-negative tumor cells (7). The gene discussed is HLA-C; the disease is neoplasm.